The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 27.00
Ask: 28.00
Change: -0.50 (-1.79%)
Spread: 1.00 (3.704%)
Open: 28.00
High: 29.00
Low: 27.50
Prev. Close: 28.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 07:00

RNS Number : 1837S
Renalytix AI PLC
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Renalytix AI Plc

213800NTOH3FK3WER551

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

 

02nd July 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

06th July 2020

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

59,416,134

Position of previous notification (if

applicable)

3.11%

-

3.11%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWL4Y04 (L&G)

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Group (Direct)

Below 3%

Below 3%

 

Legal & General Assurance Society (Direct)

 

Below 3%

 

Below 3%

 

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Group (Direct)

Below 3%

Below 3%

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Go ETF Solutions

Below 5%

Below 5%

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

 

 

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 59,416,134

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

06/07/2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFZGGNRVNGGZM
Date   Source Headline
24th Oct 20237:00 amRNSDirectorate change
17th Oct 20237:00 amRNSIssue of Shares
6th Oct 20237:00 amRNSUS Patent Office Allows Patent Claims for IP
3rd Oct 20233:13 pmRNSIssue of Shares
3rd Oct 20237:00 amRNSMedicare prices kidneyintelX.dkd at $950
28th Sep 20237:00 amRNSRenalytix Reports Full Year Fiscal 2023 Results
25th Sep 20237:00 amRNSNotice of Results
22nd Sep 20237:00 amRNSPayer coverage expansion of KidneyIntelX
7th Sep 20237:00 amRNSAppointment of Chief Business Officer
21st Aug 20237:00 amRNSBusiness Update
3rd Aug 20239:10 amRNSRSU vesting for employees
3rd Aug 20237:00 amRNSFormation of Clinical Advisory Board
21st Jul 20237:00 amRNSVector Pharma Middle East Distribution Agreement
17th Jul 20231:43 pmRNSIssue of Shares - Replacement
17th Jul 20237:00 amRNSIssue of Shares
7th Jul 20237:00 amRNSKidneyIntelX evidence presented at ADA
6th Jul 20235:38 pmRNSGrant of Share Options
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSFDA Approves KidneyIntelX.dkd™
15th Jun 20237:00 amRNSPresentation of Scientific Data
9th Jun 20237:00 amRNSFinancial Results for Q3 of Fiscal Year 2023
8th Jun 20233:30 pmRNSResult of General Meeting
5th Jun 20237:00 amRNSNotice of Q3 Results
25th May 20237:00 amRNSEVERSANA® partnership for KidneyIntelX
22nd May 20237:00 amRNSExpansion of insurance coverage for KidneyIntelX
11th May 20237:00 amRNSNotice of GM and Posting of Circular
19th Apr 20237:00 amRNSReal-World Evidence Shows KidneyIntelX™ Utility
12th Apr 20237:00 amRNSPositive Data Release at NKF Conference
30th Mar 20237:00 amRNSHalf-year Report
27th Mar 202312:50 pmRNSBusiness Update - Replacement
27th Mar 20237:00 amRNSBusiness Update
22nd Mar 20237:00 amRNSNotice of Results
21st Mar 20232:05 pmRNSSecond Price Monitoring Extn
21st Mar 20232:00 pmRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSUpdate on FDA De Novo Authorization Process
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSIssue of Shares
10th Feb 20233:13 pmRNSHolding(s) in Company
10th Feb 20232:01 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSRENX to Participate in the BTIG MedTech Conference
8th Feb 20237:00 amRNSRenalytix announces a c.$20.3m private placement
26th Jan 20237:00 amRNSRenalytix and Partners Awarded $10 Million Grant
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSCompletes Agreement with Veterans Administration
19th Dec 202212:01 pmRNSResult of AGM
1st Dec 20227:00 amRNSClinical utility study data: further highlights
30th Nov 20227:00 amRNSResults for First Quarter of Fiscal Year 2023
29th Nov 20227:00 amRNSPublication of new real world evidence
22nd Nov 20227:00 amRNSNotice of Q1 FY23 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.